par Metz, T.;Fink, Wolfram
;Vereecken, Pierre 
Référence Immunotherapy: Activation, Suppression and Treatments, Nova Science Publishers, Inc., page (175-180)
Publication Publié, 2010-01
;Vereecken, Pierre 
Référence Immunotherapy: Activation, Suppression and Treatments, Nova Science Publishers, Inc., page (175-180)
Publication Publié, 2010-01
Partie d'ouvrage collectif
| Résumé : | Malignant melanoma is the most aggressive form of skin cancer with the highest mortality. During the past few decades, the incidence of cutaneous melanoma has been rising in both sexes in almost all developed countries. [1] The prognosis of malignant melanoma is strongly related to the stage at which it is detected: patients with early diagnosed and surgically excised tumours have a high probability of complete cure. [2, 3] However, the 5-year survival for patients with regional lymph node invasion is only 54% [4], for patients with disseminated melanoma the prognosis is extremely poor with a 5- year survival of about 6 % and a median survival duration of 7.5 months [5, 6] despite a variety of therapeutical efforts that have been made. For disseminated malignant melanoma, the appropriate systemic medical treatment is still controversial. CTLA-4 inhibition is a new emerging immunotherapeutical approach in malignant melanoma patients. We will discuss this therapeutic priciple in our review. |



